How Big Is the Hepatitis B Market | Forecast & Segmentation 2031

Q: What is the current size of the hepatitis B market?

The hepatitis B market was valued at USD 1.3 Billion in 2024 and is expected to reach USD 1.93 Billion by 2031

Q: What is the growth rate of the hepatitis B market?

The market is expected to grow at a CAGR of 7.4% between 2025 and 2031.

Q: What is driving the growth of the hepatitis B market?

Rising global prevalence of hepatitis B infections, increased vaccination initiatives, improved diagnostics, and growing access to antiviral therapies are key growth drivers.

Q: Which treatments are commonly used for hepatitis B?

Nucleos(t)ide analogues like tenofovir and entecavir, interferon therapies, and preventive vaccines are commonly used.

Q: What are the major challenges in the hepatitis B market?

Challenges include limited awareness in low-income regions, high treatment costs, stigma associated with the disease, and the absence of a complete cure.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6146

Publication Date: Jul 2025

How big is the Hepatitis B Market?

According to 6Wresearch internal database and industry insights, the Global Hepatitis B Market was valued at USD 1.3 Billion in 2024 and is expected to reach USD 1.93 Billion by 2031, growing at a compound annual growth rate of 5.90% during the forecast period (2025-2031).

This growth is fueled by rising global vaccination programs, increasing screening rates, and demand for advanced antiviral therapies.

View Main Report

Schedule Analyst Call

Key Growth Drivers of the Hepatitis B Market

Rising global incidence of chronic hepatitis B infections
Government-led awareness and immunization programs
Increased use of diagnostics and antiviral treatments
Advancements in combination therapy development
Support from WHO and health organizations for eradication efforts

Hepatitis B Market Trends

Hepatitis B market is witnessing consistent growth driven by expanded national immunization programs, especially in Asia and Sub-Saharan Africa, where the disease burden is highest. Oral antiviral therapies like tenofovir and entecavir continue to dominate due to their proven efficacy and safety profile. There's growing adoption of next-generation diagnostics, including real-time PCR and automated serological testing, for faster and more accurate detection. Pharmaceutical firms are investing heavily in therapeutic vaccines and combination treatments targeting chronic hepatitis B.

Emerging Developments in the Hepatitis B Market

The hepatitis B market is undergoing notable innovation, particularly in the development of functional and curative therapies. Biotech firms are advancing investigational drug candidates such as capsid assembly modulators, RNA interference (RNAi)-based therapies, and entry inhibitors, aiming to achieve a functional cure by suppressing surface antigen levels. Companies are also exploring therapeutic vaccines that could stimulate the immune system to fight chronic infection more effectively. Additionally, combination regimens involving immune modulators and antivirals are being tested in late-stage clinical trials to enhance treatment outcomes.